Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Observational × Efficacy, Team × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 436 Breast Neoplasms 389 Lung Neoplasms 216 Prostatic Neoplasms 194 Colorectal Neoplasms 180 Carcinoma, Non-Small-Cell Lung 161 Pancreatic Neoplasms 138 Stomach Neoplasms 119 Carcinoma, Hepatocellular 117 Ovarian Neoplasms 101 Esophageal Neoplasms 89 Head and Neck Neoplasms 84 Multiple Myeloma 82 Melanoma 78 Urinary Bladder Neoplasms 77 Uterine Cervical Neoplasms 73 Liver Neoplasms 70 Brain Neoplasms 67 Lymphoma 65 Hematologic Neoplasms 64 Endometrial Neoplasms 63 Disease 61 Rectal Neoplasms 57 Neoplasm Metastasis 54 Leukemia, Myeloid, Acute 51 Leukemia 50 Colonic Neoplasms 50 Precursor Cell Lymphoblastic Leukemia-Lymphoma 47 Carcinoma, Renal Cell 47 Thyroid Neoplasms 45

Interventions

pembrolizumab 1 Nivolumab 1 Immune Checkpoint Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06693440 2024-11-18

The Immune Assessment of PD-1 Antibody Therapy in Tumor

Henan Cancer Hospital

Efficacy, Team

Data powered by HemOnc (CC BY 4.0) Colophon ⚡